Discussion
Before the end of the year, Arexera Therapeutics is planning to launch a Phase 1 clinical trial testing its experimental therapy ATL-101 in people with Huntington’s disease. According to a company press release, the upcoming trial is expected to test one-time treatment with ATL-101 at various doses,…